^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HERtiCAD (trastuzumab biosimilar)

    i
    Other names: BCD-022
    Company:
    Biocad
    Drug class:
    HER2 inhibitor
    Related drugs:
    4years
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. (PubMed, BMC Cancer)
    Thus, results of this study have demonstrated therapeutic equivalence of trastuzumab biosimilar BCD-022 and referent trastuzumab drug.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • HERtiCAD (trastuzumab biosimilar)